United Therapeutics Q3 2026 Earnings: Revenue Rises as R&D Spending Pressures Profit

United Therapeutics (NASDAQ: UTHR) reported Q3 2026 revenue of $832.5 million, up 4% from $799.5 million a year earlier, while diluted EPS fell 20% to $5.71 from $7.16. Net income declined 24% as higher research spending outweighed revenue growth and a modest improvement in gross margin, with Tyvaso DPI and Orenitram providing the main product-level gains.

Core Earnings Data

Revenue reached a quarterly record, but the 4% increase did not translate into higher earnings. Cost of sales declined slightly despite the revenue gain, lifting estimated gross margin by about 0.7 percentage points, so the profit contraction primarily occurred below the gross-profit line.

R&D expense rose 119% to $279.2 million, driven by in-process R&D associated with the Thymmune acquisition and increased spending on manufactured-organ, organ-alternative, and cardiopulmonary programs. That increase pushed operating income down approximately 21% and reduced operating margin by about 11.6 percentage points.

The effective tax rate also increased to 31% from 23%, primarily because the Thymmune-related IPR&D expense was not deductible and was instead capitalized into the tax basis of the acquired stock.

Business and Product Performance

Tyvaso remained the largest revenue source, generating $503.8 million, or about 61% of total revenue. Its two formulations continued to diverge: Tyvaso DPI grew 13%, while Nebulized Tyvaso declined 12%.

Tyvaso DPI benefited primarily from a $43.9 million increase related to quantities sold and from higher pricing, partly offset by increased gross-to-net deductions. Nebulized Tyvaso was pressured by a $20.0 million reduction related to U.S. quantities sold, although a price increase partially offset the decline.

United Therapeutics said competitive therapies negatively affected sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin during the quarter. Orenitram’s growth was mainly supported by a $14.9 million increase related to quantities sold and higher pricing, partly offset by increased gross-to-net deductions.

U.S. revenue increased to $808.5 million from $774.8 million, while rest-of-world revenue decreased to $24.0 million from $24.7 million. The company therefore remained highly dependent on the U.S. market.

Profitability, Liquidity, and Capital Allocation

Reported selling, general, and administrative expense declined 20% to $146.4 million, but the decrease reflected a $66.5 million reversal of a previously accrued Sandoz litigation liability. The matter was settled in connection with United Therapeutics’ agreement with Liquidia Technologies and dismissed on October 28, 2026.

Underlying cost trends were less favorable. General and administrative expense excluding the litigation accrual increased because of higher headcount, legal expenses, and consulting costs. Sales and marketing expense rose 45% to $41.0 million, mainly because of higher personnel expense.

Interest income fell to $33.7 million from $46.4 million after the company sold marketable securities to fund accelerated share repurchase agreements. Other income increased to $34.2 million from $6.1 million, primarily because of realized and unrealized gains on equity securities.

United Therapeutics ended the quarter with $3.54 billion in cash, cash equivalents, and marketable investments. Total assets were $7.03 billion, compared with $758.1 million of liabilities and $6.28 billion of stockholders’ equity.

The company repurchased 980,394 shares during the quarter. Its September accelerated share repurchase used the remaining $477.6 million under the March 2026 authorization, leaving no capacity under that program. In October, the board approved a separate repurchase program of up to $2.0 billion through October 21, 2027.

Recent Insider Transactions

The supplied Yahoo Finance data lists 10 recent indirect transactions by CEO Martine A. Rothblatt across five dates. Each date pairs a derivative-security exercise conversion at $117.76 per share with a sale; the transaction data does not establish the reason for the sales.

Risks Investors Should Monitor

• Competition in pulmonary hypertension treatments: United Therapeutics said competing therapies negatively affected Nebulized Tyvaso, Tyvaso DPI, and Remodulin. Continued pressure could constrain volume growth and alter the product mix.
• Dependence on Tyvaso: Total Tyvaso generated about 61% of quarterly revenue. The decline in the nebulized formulation shows that growth in Tyvaso DPI must offset weakness elsewhere in the franchise.
• Higher development spending: R&D expense more than doubled as the company funded acquired IPR&D and expanded organ and cardiopulmonary programs. Continued spending at elevated levels could keep operating margins below the prior-year level.
• Underlying operating-cost growth: Reported SG&A benefited from a litigation-accrual reversal, while headcount, legal, consulting, and sales expenses increased. Future quarters may not receive a similar benefit from that reversal.
• Lower interest income following repurchases: Securities sold to fund share repurchases reduced interest income, increasing the importance of operating performance and other investment gains to overall earnings.

Summary

United Therapeutics produced modest Q3 revenue growth as Tyvaso DPI and Orenitram gains outweighed weaker Nebulized Tyvaso and other products. Gross margin improved slightly, but the sharp increase in R&D spending and a higher tax rate drove lower operating income, net income, and EPS. The main issues to monitor are competitive pressure across the Tyvaso and Remodulin franchises, the pace and returns of pipeline investment, underlying personnel and legal costs, and the effect of continued capital deployment on liquidity and non-operating income.